Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could dropping aspirin early after stent surgery be safer?

NCT ID NCT07684742

Disease control Sponsor: Gyeongsang National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial investigates whether patients with acute coronary syndrome can safely stop taking aspirin soon after a heart stent procedure and continue with only a potent antiplatelet drug (ticagrelor or prasugrel). The standard approach is to take both aspirin and a P2Y12 inhibitor for 12 months. The study aims to see if early aspirin discontinuation reduces bleeding complications without increasing the risk of heart attacks, stent clots, or death. About 1,900 participants who had successful ultrasound-guided stent placement will be randomly assigned to either early single therapy or standard dual therapy and followed for one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ticagrelor or prasugrel (P2Y12 inhibitors)
What this could lead to
If successful, this could simplify post-stent medication by allowing patients to stop aspirin early, potentially reducing bleeding complications while still protecting against heart attacks and stent clots.
What could go wrong
This is a Phase 4 trial, but the approach is still being tested. Stopping aspirin early might increase the risk of stent thrombosis or heart attack in some patients. Results may not apply to all heart patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,900 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>=18 years 2. Diagnosis of acute coronary syndrome, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina (UA) 3. Successful IVUS-guided PCI with drug-eluting stent implantation 4. Randomization within 96 hours after PCI 5. Written informed consent Exclusion Criteria: 1. Planned staged PCI or CABG 2. PCI failure, including no-reflow, major dissection, or thrombosis 3. Need for oral anticoagulation 4. Major bleeding within 30 days 5. History of hemorrhagic stroke or ischemic stroke within 6 months 6. Platelet count \<100,000/mm3 or WBC count \<3,000/mm3 7. Contraindication to aspirin, ticagrelor, or prasugrel 8. Life expectancy \<1 year 9. Current or potential pregnancy 10. Investigator deems participation inappropriate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndromes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome acute myocardial infarction intermediate coronary syndrome Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndromes NSTEMI STEMI Unstable angina

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gyeongsang National University Hospital

    Jinju, Gyeongsangnam-do, 52727, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.